Home
/
RELIGION & LIBERTY ONLINE
/
Why cheap drugs from Canada won’t reduce U.S. Drug prices
Why cheap drugs from Canada won’t reduce U.S. Drug prices
Nov 24, 2025 4:01 AM

If you suffer from acid reflux, your doctor may prescribe Nexium. But at $9 a pill, the price is enough to give you a worse case of heartburn.

That’s the lowest price in the U.S. If you live in Canada, though, you can get the drug for less than a $1 a pill.

This price disparity leads many politicians to think the solution is obvious: Americans should just buy drugs from Canada or other countries where they are cheaper.

Its plan supported by economic liberals like President Trump and Bernie Sanders. Several years ago Sen. Amy Klobuchar (D-Minn.) and John McCain (R-Az.) twice introduced legislation to allow Americans to order up to a 90-day supply of medicines from a licensed Canadian pharmacy. The Democratic Party even made it a part of their party platform in 2016.

If this seems too easy, it’s because it’s an economically ignorant idea. Writing in the Harvard Business Review a few years ago, Rafi Mohammed explained why this strategy won’t work:

The reason why pharmaceutical prices are relatively high in the U.S. is panies employ mon strategy called differential pricing. This strategy targets specific segments with different prices. So instead of having the same price for everyone, the goal is to tailor the “right” price to various segments. Movie theaters, for instance, use differential pricing by offering lower prices to students and seniors. The assumption is students and seniors are sensitive to price, sooffering targeted discounts to them is profitable. As a result, moviegoers seated next to each other often have paid different prices.

For differential pricing to be profitable, targeted segments have to be easily identifiable, and,most importantly, arbitrage cannot occur. By arbitrage, I mean those who receive discounts don’t resell to customers who are currently paying more. This strategy works well at cinemas: it’s easy to identify seniors/students, and since tickets are sold individually at the door, enterprising seniors/students typically aren’t reselling discounted tickets for a profit.

Why are drug prices so much higher in the U.S.? The answer is straightforward: most countries regulate prices or have a single-payer health care system, in which the government pays for citizens’ health care costs. In a single-payer system, the government buys all a country’s pharmaceuticals, and it has leverage in “take it or leave it” negotiations with panies.

Mohammed’s explanation is helpful, but it’s also plete. What he doesn’t mention is the reason whythe price differential for drugs can work: because expensive medicines in the U.S. subsidize the creation of drugs for the entire world.

According to the pharmaceutical giant Eli Lilly, the average cost to discover and develop a new drug is between $800 million to $1.2 billion, and the average length of time from discovery to patient is 10 to 15 years.

If a product costs $1 billion to produce and bring to market, that is the initial fixed cost. Think of it this way: the initial cost to produce the very first Nexium pill is roughly $1 billion. But once that first pill is created, the cost to produce the second, third, fourth, . . . hundred thousandth pill is very low. But if the initial fixed cost cannot be recovered, then pany will lay out the money and spend a decade or more creating the product. New medications will simply not exist.

This point should be obvious—and yet it is widely overlooked and ignored. People see a drug, like Nexium, and forget that it only exists because a pany believed it could recoup the cost of research and development and make a profit by selling the medicine. But how is pany able to earn back the initial billion dollar fixed costs? By charging some buyer—whether a government, HMO, pany or individual—a price that will cover the initial fixed costs.

Once that fixed costs of creating the drug is covered, though, the price can be reduced since the remaining variable costs (e.g., the cost to produce each individual pill) tend to be relatively low. And this brings us to why you, as an American, pay a higher price for a drug that Canadians and Europeans get much cheaper.

To make it easier to understand, let’s imagine that a medicine is created to cure a single disease in three patients living in America, Canada, and France. Now let’s say that the patient in America pays all of the fixed cost ($1 billion), plus the variable cost for one pill (50 cents), plus 50 cents in profit for pany. In total, the American ends up paying $1,000,000,001 for a single pill.

The pany is happy because they recouped their costs and made a profit (50 cents). Canada and France say that they too want to buy the drug, but they will pay only $1. The pany agrees to sell the pill for $1 to both Canada and France because an additional $1 profit is better than $0 in additional profit. Everyone is happy.

Well, maybe not everyone. The American may say that it wasn’t fair for them to pay all the fixed costs —and they’d be right. In our example, Canada and France are free riders that are able to take advantage of the lower costs only because the Americans have already paid the exorbitant fixed costs. The American subsidized the cost of the drug for the patients in the other countries.

This is exactly what happens with most drugs. Very few new medicines are produced in countries that have government restrictions on drug prices. And almost no new drugs would be produced if all countries had government restrictions on drug prices. Without the willingness of the United States to pay the higher prices, the drugs would never e into existence. Countries like Canada and France are like roommates who let you pay full price for a pizza but expect you to give them a slice in exchange for a few pennies they found in the couch.

Which brings us back to the “reimport the drugs” strategy. The reason this approach won’t work is because once Americans stop subsidizing the drugs for the rest of the world, panies will not be able to recoup their costs for R&D. paniessimply won’t be able to afford to create innovative new medicines. That makes everyone worse off than before.

Ultimately, socialized medicine—in the form of government-imposed drug pricing—doesn’t work for the same reason Margaret Thatcher said socialist governments don’t work: “They always run out of other people’s money.”

Comments
Welcome to mreligion comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
RELIGION & LIBERTY ONLINE
Samuel Gregg: Social Security and Subsidiarity
In the National Catholic Register, Kathryn Jean Lopez looks at the current debate on Social Security and asks: “So, is it a Ponzi scheme? Is it time to blow it up? Are these questions freaking people out — and missing the point?” Acton Research Director Samuel Gregg is extensively quoted in the article. Here he is explaining how the principle of subsidiarity plays into the debate. “Integral human development requires us to make free choices and to be assisted in...
Faith and Work, Politics and Jobs
Reactions from munities to last week’s jobs speech from President Obama are running the political gamut, as one might expect. Over at Think Christian, my piece has garnered some rather vociferous response. And at the Faith in Public Life blog, Jessica Barba piles some responses that focus on “the need for serious job-creation legislation.” The problem here is that while a society with opportunities for employment for all is seen as a moral imperative, the primary agent responsible for creating...
On Locke and Aquinas: Reason, Will, and Law
Greg Forster’s latest response to Sam Gregg, Acton’s director of research, on the utility of John Locke’s thought today is up over at Public Discourse. There’s a lot to learn from reading these exchanges, but right now I want to focus just briefly on one of the criticisms that Sam levels against Locke. Comparing Locke’s definition of Law to that of Aquinas, Sam finds Locke to be quite wanting. For Locke, “Law’s formal definition is the declaration of a superior...
Solyndra and the False Hope of Green Jobs
In this week’s Acton Commentary, “Solyndra and the False Hope of Green Jobs” I look at the original problem with federally funded Green Jobs. The Solyndra debacle has been called a “microcosm of Obamanomics,” an example of what always happens when the Federal Government starts handing out $500 million checks. That’s true, but it’s a microcosm of something more — of an economy that’s lost it’s understanding of vocation. We stumble around trying to “create jobs” by Congressional action without...
Pope Benedict Greets Acton Institute
Pope Benedict XVI warmly greeted a group of 23 Acton Institute staff and supporters on pilgrimage at his Castel Gandolfo summer palace this past Sunday, September 18. During the traditional Sunday Angelus audience inside the papal summer palace courtyard, Benedict delivered an inspiring talk on Christ’s parable of the workers in the vineyard — a most appropriate Christian teaching upon which the Acton Institute often reflects and articulates during its economics seminars to religious students and business professionals throughout the...
Looking to Business for Disaster Relief
I have written quite a bit on the church response to natural disasters here at Acton. “The Church and Disaster Relief: Shelter from the Stormy Blast” was the feature piece in the last issue of Religion & Liberty. John Tozzi over at has written an excellent article highlighting Louisiana’s outreach to the munity during natural disasters. From the article: As Hurricane Gustav bore down on Louisiana in 2008, state officials wanted to avoid the food shortages that had followed Katrina...
In the Octagon: Ron Paul vs. Religious Left
Even though Ron Paul clarified himself at the Tea Party debate, and explained that he doesn’t think those who can’t afford medical care should be laid out on the curb to die, the Left went about painting his answer as morally abominable. Before we deal with their abuse of Christian doctrine, let’s see what Paul said: I practiced medicine before we had Medicaid, in the early 1960s, when I got out of medical school. I practiced at Santa Rosa Hospital...
Strange Bedfellows? The Propserity Gospel and Liberation Theology
Preacher of the prosperity gospel and swindler of poor Brazilians Bishop Edir Macedo was charged last week with embezzeling hundreds of millions of dollars from his Universal Church of the Kingdom of God. Until I read about the case (h/t Get Religion), I didn’t realize that the prosperity gospel had much of a foothold outside American Pentecostal traditions. It makes perfect sense though that it should be the heir to liberation theology in Latin America. The Catholic Church fought back...
Rev. Sirico: ‘Jobs & deficits — the moral equation’
Writing in today’s Pittsburgh Tribune-Review, Rev. Robert A. Sirico, president and co-founder of the Acton Institute: Jobs & deficits — the moral equation By Rev. Robert A. Sirico Thursday, September 15, 2011 The Genesis account of creation tells us that from the beginning, humanity was created to work. God puts Adam in the garden to “work and watch over it.” The Scripture provides an insight into our nature: We are all, man and woman, called into this life to find...
Webcast: Acton’s Michael Miller in Colson’s ‘Doing the Right Thing’
In the Grand Rapids Press, reporter Ann Byle interviews Acton’s Michael Miller about a live, national webcast on Sept. 24 of the Colson Center’s “Doing the Right Thing: An Exploration of Ethics.” Byle notes that the webcast “features a live panel discussion with [Chuck] Colson, experts Del Tackett, Robert George, John Stone-street and host Eric Metaxas. Grand Rapids-based Acton Institute’s Michael Miller also will participate as a panelist, thanks to his work as a research fellow and expert on the...
Related Classification
Copyright 2023-2025 - www.mreligion.com All Rights Reserved